GSK To Pay $92 Mil. To Settle Augmentin Antitrust Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will reserve an additional $220 mil. to cover “certain other legal matters.” Charge to quarterly earnings will be offset by gains from equity investments and other income.